SPRY
ARS Pharmaceuticals Inc.
$9.97
+$0.18(+1.79%)
50
Overall
--
Value
50
Tech
--
Quality
Market Cap
$929.96M
Volume
1.24M
52W Range
$9.38 - $18.90
Target Price
$32.50
Order:
Income Statement
| Metric | Trend | Chart | 2021 Dec | 2022 Dec | 2023 Dec | 2024 Dec |
|---|---|---|---|---|---|---|
| REVENUE | ||||||
| Total Revenue | $5.5M | $1.3M | $30.0K | $89.1M | ||
| Total Revenue | $5.5M | $1.3M | $30.0K | $89.1M | ||
| COST OF GOODS SOLD | ||||||
| Cost of Revenue | -- | -- | -- | $977.0K | ||
| GROSS PROFIT | ||||||
| Gross Profit | $5.5M | $1.3M | $30.0K | $89.1M | ||
| OPERATING EXPENSES | ||||||
| Operating Expenses | $25.0M | $36.8M | $67.5M | $92.2M | ||
| Research & Development | $20.3M | $18.4M | $20.3M | $19.6M | ||
| Research Expense | $20.3M | $18.4M | $20.3M | $19.6M | ||
| Selling, General & Administrative | $4.7M | $18.5M | $47.3M | $71.7M | ||
| Selling & Marketing Expenses | $476.0K | $603.0K | -- | $12.5M | ||
| General & Administrative Expenses | $4.7M | $18.5M | $47.3M | $71.7M | ||
| Promotion & Advertising | -- | -- | -- | $12.5M | ||
| Salaries & Wages | -- | -- | -- | $14.5M | ||
| Depreciation & Amortization | $800.0K | $100.0K | $100.0K | $100.0K | ||
| Depreciation & Amortization | $800.0K | $100.0K | $100.0K | $100.0K | ||
| Amortization | $2.0K | -- | -- | $7.4M | ||
| Other Operating Expenses | $-206.0K | $-373.0K | $-475.0K | $-583.0K | ||
| OPERATING INCOME | ||||||
| Operating income | $-19.5M | $-35.5M | $-67.5M | $-3.1M | ||
| EBITDA | $-20.2M | $-35.2M | $-67.5M | $1.1M | ||
| NON-OPERATING ITEMS | ||||||
| Interest Expense (Non-Operating) | $-106.0K | -- | -- | -- | ||
| Net Non-Operating Interest Income/Expense | $106.0K | -- | -- | -- | ||
| Gain on Sale of Securities | -- | $-140.0K | -- | -- | ||
| Other Income/Expense | $789.0K | $834.0K | $-13.2M | $-11.4M | ||
| Other Special Charges | $-789.0K | $974.0K | $13.2M | $11.4M | ||
| PRE-TAX INCOME | ||||||
| EBIT | $-20.2M | $-35.5M | $-67.5M | $8.3M | ||
| Pre-Tax Income | $-20.2M | $-34.7M | $-54.4M | $8.3M | ||
| INCOME TAX | ||||||
| Tax Provision | $-9.0K | $-21.0K | $-88.0K | $288.0K | ||
| NET INCOME | ||||||
| Net Income | $-20.2M | $-34.7M | $-54.4M | $8.0M | ||
| Net Income (Continuing Operations) | $-20.2M | $-34.7M | $-54.4M | $8.0M | ||
| Net Income (Discontinued Operations) | $-20.2M | $-34.7M | $-54.4M | $8.0M | ||
| Net Income (Common Stockholders) | $-20.2M | $-34.7M | $-54.4M | $8.0M | ||
| Normalized Income | -- | -- | -- | $8.2M | ||
| TOTALS | ||||||
| Total Expenses | $25.0M | $36.8M | $67.5M | $92.2M | ||
| SHARE & EPS DATA | ||||||
| Average Shares Outstanding | $34.9M | $40.0M | $95.2M | $96.9M | ||
| Average Shares Outstanding (Diluted) | $34.9M | $40.0M | $95.2M | $102.4M | ||
| Shares Outstanding | $35.1M | $94.4M | $96.5M | $98.1M | ||
| Basic EPS | $-2.56 | $-0.87 | $-0.57 | $0.08 | ||
| Basic EPS (Continuing Operations) | $-2.56 | $-0.87 | $-0.57 | $0.08 | ||
| Diluted EPS | $-2.56 | $-0.87 | $-0.57 | $0.08 | ||
| Diluted EPS (Continuing Operations) | -- | $-0.87 | $-0.57 | $0.08 | ||
| OTHER METRICS | ||||||
| Other Gand A | $4.7M | $18.5M | $47.3M | $71.7M | ||
Financial data is updated quarterly and may not reflect the most recent earnings.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | SPRY | $9.97 | +1.8% | 1.24M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get ARS Pharmaceuticals Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW